Zera Intein Protein Solutions, ZIP Solutions, is a Barcelona based biotech company dedicated to the discovery, development, and commercialization of innovative protein technologies for the pharmaceutical and biotech markets.
Our two proprietary technologies, ZERA and SPLITTERA, are powerful tools for the production and processing of recombinant proteins and for the improvement of biotherapeutics' performance. Both technologies are subjected to continuous upgrade cycles and constant search for novel applications in collaboration with academic and industrial partners.
ZIP’s highly experienced team brings all its knowledge and skills to co-develop and transfer projects to customers, meeting the objectives ensuring success of the project.
Miriam Bastida, PhD. MANAGING DIRECTOR
Dr. Bastida holds a PhD in Molecular Biology. She has been in the forefront of the core invention of ZIP’s technology portfolio. Over the last 10 years, she has developed these technologies from the synthesis of advanced recombinant proteins to applied product development for commercial products.
She is a scientific co-founder of the company ERA Biotech. Since inception, she has been managing scientific projects, moving gradually in the management of R&D collaborative projects with international companies. She was promoted to become the Managing Director of ERA Biotech in January 2013. In February 2015 ZIP Solutions acquired ERA Biotech, and Dr. Bastida is since then Managing Director of ZIP Solutions.
Núria Martínez, PhD. R&D Project Manager
Dr. Núria Martínez is R&D Project Manager in ZIP Solutions. She holds a PhD in Biochemistry and a
Master in Integrated Project Management. She's been the responsible for the company projects involving proprietary split-intein technology (Splittera) since 2013, managing internal as well as customer’s projects. Her main expertise areas are protein expression and purification, and enzyme characterization.
Marco Archinti, PhD. R&D Project Manager & IP Manager
Dr. Marco Archinti is R&D Project Manager in ZIP Solutions. He holds a PhD in Cell and Molecular Biology. He’s been managing R&D Projects since 2012, after obtaining his Master in Integrated Project Management at the Barcelona University. Currently, he is in charge of the management of intellectual property as well as of internal projects involving the exploitation of the proprietary technology for the improvement of vaccines, Zera®, both as DNA and as protein formulations.